Bilix Co., Ltd. news
Interest in bilirubin is high worldwide. This is because bilirubin has already received attention as a substance that has strong antioxidant effects and immunomodulatory effects through 30,000 papers from several decades ago. However, there were clear limitations in developing it as a new drug. This is because it is extremely hydrophobic, insoluble in water.
Billix has successfully completed the Series A round. It raised 14 billion won in an investment round in a year and a half. Not only financial investors (FI) but also strategic investors (SI) such as Estec Pharma and Soulbrain Holdings continued to participate.
According to related industries on the 25th, Bilix recently completed attracting 14 billion won in Series A investment.&n
“We will make ‘bilirubin,’ a substance with antioxidant effects that removes harmful free radicals, as a disease treatment for the first time in the world.”
“Over 20,000 papers since 1987 have shown that bilirubin has a therapeutic effect on various diseases,” said Myung-Lip Kim, CEO of Bilix, a bio company developing new drugs that we met last week at the headquarters in Yongin, Gyeonggi Province. It has been s
This is the IR video of Vilix Co., Ltd., the 4th KBIC Star Day of the Health Industry Innovation and Startup Center. Introducing the treatment based on bilirubin nano-platform technology.
“Bilix Co., Ltd.” succeeded in chemical synthesis of bilirubin for the first time in the world- The nanoparticle itself: BRIXELLE-INFLA anti-inflammatory drug
1 Establishment of new drug pipeline with bilirubin platform technology
Securing global competitiveness by increasing corporate value
“I want to give hope to those who are living a difficult life with an incurable disease”
[IB Tomato Lim Seong-ji] “The new drug development industry is a specialized area that is difficult for ordinary investors and shareholders to understand, and it is difficult